3 Growth Companies With High Insider Ownership Seeing Up To 33% Earnings Growth

In the current global market landscape, uncertainty surrounding policy changes and economic indicators has led to mixed performances across various sectors. Amidst this backdrop, identifying growth companies with high insider ownership can be a strategic approach, as these firms often align management interests with shareholder value and may offer resilience in volatile conditions.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
People & Technology (KOSDAQ:A137400)	16.4%	37.3%
Archean Chemical Industries (NSEI:ACI)	22.9%	43%
Kirloskar Pneumatic (BSE:505283)	30.3%	26.3%
Seojin SystemLtd (KOSDAQ:A178320)	31.1%	52.4%
Medley (TSE:4480)	34%	31.7%
Findi (ASX:FND)	34.8%	71.5%
Global Tax Free (KOSDAQ:A204620)	19.9%	78.4%
Plenti Group (ASX:PLT)	12.8%	120.1%
UTI (KOSDAQ:A179900)	33.1%	134.6%
Brightstar Resources (ASX:BTR)	16.2%	84.6%

Click here to see the full list of 1535 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

EQT (OM:EQT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: EQT AB (publ) is a global private equity firm focusing on private capital and real asset segments, with a market cap of approximately SEK353.69 billion.

Operations: The company's revenue is primarily derived from its Private Capital segment at €1.28 billion and Real Assets segment at €878.70 million, with an additional contribution of €37.20 million from the Central segment.

Insider Ownership: 12.3%

Earnings Growth Forecast: 33.5% p.a.

EQT is positioned for growth with a forecasted annual earnings increase of 33.5%, surpassing the Swedish market's average. Despite trading below its estimated fair value, EQT has no recent substantial insider buying or selling activity. The firm actively engages in mergers and acquisitions, including potential involvement in acquiring Rapid7 and exploring sales of assets like Banking Circle and AGS Health. Such strategic maneuvers indicate EQT's commitment to expanding its portfolio while enhancing shareholder value through high return on equity projections.

• Click here and access our complete growth analysis report to understand the dynamics of EQT.
• According our valuation report, there's an indication that EQT's share price might be on the expensive side.

Kingsoft (SEHK:3888)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kingsoft Corporation Limited operates in the entertainment and office software and services sectors across Mainland China, Hong Kong, and internationally, with a market cap of approximately HK$43.12 billion.

Operations: The company's revenue is derived from its online games segment, which generated CN¥4.93 billion, and its office software and services segment, which contributed CN¥4.91 billion.

Insider Ownership: 20.4%

Earnings Growth Forecast: 21% p.a.

Kingsoft demonstrates significant growth potential with earnings expected to increase 21% annually, outpacing the Hong Kong market. Recent Q3 results show net income of CNY 413.45 million, a substantial rise from CNY 28.49 million the previous year. Despite trading at a discount to its estimated fair value, Kingsoft's revenue growth is slower than desired but still exceeds market averages. The company has completed share buybacks totaling HKD 592.96 million, reflecting confidence in its future prospects.

• Click to explore a detailed breakdown of our findings in Kingsoft's earnings growth report.
• Our valuation report unveils the possibility Kingsoft's shares may be trading at a premium.

APT Medical (SHSE:688617)

Simply Wall St Growth Rating: ★★★★★★

Overview: APT Medical Inc. focuses on the research, development, manufacturing, and supply of electrophysiology and vascular interventional medical devices in China with a market cap of CN¥35.39 billion.

Operations: The company's revenue is primarily generated from its medical products segment, which amounted to CN¥1.96 billion.

Insider Ownership: 31.8%

Earnings Growth Forecast: 29.3% p.a.

APT Medical is poised for robust growth, with earnings forecast to rise 29.32% annually, surpassing the Chinese market average. Recent results for the nine months ended September 2024 show revenue at CNY 1.52 billion, up from CNY 1.21 billion a year ago, and net income reaching CNY 528.15 million compared to CNY 403.25 million previously. The company's inclusion in the FTSE All-World Index underscores its expanding market presence and potential appeal to investors seeking growth opportunities with substantial insider ownership influence.

• Get an in-depth perspective on APT Medical's performance by reading our analyst estimates report here.
• In light of our recent valuation report, it seems possible that APT Medical is trading beyond its estimated value.

Key Takeaways

• Explore the 1535 names from our Fast Growing Companies With High Insider Ownership screener here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com